SCHEMBL24068460

SCHEMBL24068460

CCOCCNC(=O)/C(C#N)=C(\C)c1ccc(-c2ccc3cc(N4CCCCC4)ccc3c2)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.38
KMT2A Q03164 6/20 0.33
MEN1 O00255 5/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
MAPT P10636 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PGR P06401 1/20 0.32
SCN9A Q15858 1/20 0.31
ERN1 O75460 1/20 0.31
KDM4E B2RXH2 1/20 0.31
GAA P10253 1/20 0.31
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19293972 0.93 APP (0.39) APPMAPTALDH1A1ERN1RXFP1
SCHEMBL21226381 0.92 APP (0.40) APPKMT2AMEN1MAPTALDH1A1
SCHEMBL18220172 0.92 APP (0.42) APPKMT2AMEN1NPC1RAB9A
SCHEMBL23134879 0.88 APP (0.34) APPKMT2AMEN1MAPTPGR
SCHEMBL21226374 0.86 APP (0.43) APPKMT2AMEN1NPC1RAB9A
SCHEMBL18220286 0.85 APP (0.34) APPKMT2AMEN1NPC1RAB9A
SCHEMBL18220189 0.85 APP (0.43) APPKMT2AMEN1NPC1RAB9A
SCHEMBL18220177 0.84 APP (0.44) APPKMT2AMEN1MAPTALDH1A1
SCHEMBL24068456 0.83 APP (0.38) APPKMT2AMEN1NPC1RAB9A
SCHEMBL17120805 0.83 APP (0.34) APPPGRSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-20210371390-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2021-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885KMT2A 4649/4885MEN1 2997/4885
US-20210371390-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885KMT2A 4649/4885MEN1 2997/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885KMT2A 4649/4885MEN1 2997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.